| Identification | Back Directory | [Name]
Deoxyarbutin | [CAS]
53936-56-4 | [Synonyms]
Deoxyarbutin
Tetrahydropyranyloxyphenol
4-[(Tetrahydro-2H-pyran-2-yl)oxy]phenol
Phenol,4-[(tetrahydro-2H-pyran-2-yl)oxy]-
Deoxyarbutin
4-[(Tetrahydro-2H-pyran-2-yl)oxy]phenol | [EINECS(EC#)]
1308068-626-2 | [Molecular Formula]
C11H14O3 | [MDL Number]
MFCD09970981 | [MOL File]
53936-56-4.mol | [Molecular Weight]
194.23 |
| Chemical Properties | Back Directory | [Melting point ]
88-89 °C(Solv: ligroine (8032-32-4)) | [Boiling point ]
349.8±32.0 °C(Predicted) | [density ]
1.174 | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly, Sonicated) | [form ]
Solid | [pka]
10.10±0.15(Predicted) | [color ]
White to Off-White | [Stability:]
Hygroscopic | [Cosmetics Ingredients Functions]
BLEACHING | [InChI]
InChI=1S/C11H14O3/c12-9-4-6-10(7-5-9)14-11-3-1-2-8-13-11/h4-7,11-12H,1-3,8H2 | [InChIKey]
GFBCWCDNXDKFRH-UHFFFAOYSA-N | [SMILES]
C1(O)=CC=C(OC2OCCCC2)C=C1 |
| Hazard Information | Back Directory | [Description]
Deoxyarbutin is a tyrosinase inhibitor (IC50 = 17.5 μM for mushroom tyrosinase).1 It reduces melanin content in isolated dark human melanocytes when used at a concentration of 1.56 μM.2 Topical administration of deoxyarbutin (5%) induces skin lightening in human skin mouse xenograft models. Deoxyarbutin also inhibits proliferation of B16/F10 murine melanoma cells (EC50 = 39.56 μM).3 It induces apoptosis and halts the cell cycle at the S phase in B16/F10 cells when used at a concentration of 50 μM. Deoxyarbutin (50 mg/kg) reduces tumor growth in a B16/F10 murine melanoma model. | [Uses]
Deoxyarbutin acts as a skin whitening agent through the inhibition of tyrosinase. A safer alternative to the use of hydroquinone and arbutin. | [Preparation]
Deoxyarbutin is a derivative of ?-arbutin, obtained by removal of hydroxyl groups from the glucose side-chain of ?-arbutin.
| [Synthesis]
Under nitrogen protection, 3,4-dihydro-2H-pyran (19.1 g, 227.0 mmol) was dissolved in a solution of dichloromethane (200 ml) containing pyridinium p-toluenesulfonate (PPTS) (5.7 g, 22.7 mmol). After cooling the reaction system to 10°C, a solution of hydroquinone (25.0 g, 227.0 mmol) in dichloromethane (100 ml) was added slowly and dropwise. Subsequently, the reaction mixture was gradually warmed to 25°C and stirred continuously for 16 hours. After completion of the reaction, the mixture was poured into water (500 ml) and the aqueous layer was extracted with dichloromethane. The organic layers were combined and washed sequentially with saturated aqueous sodium chloride solution and saturated aqueous sodium bicarbonate solution, then dried with anhydrous magnesium sulfate. The organic phase was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (eluent: toluene/ethyl acetate=5:1, v/v) to afford 4-((tetrahydro-2H-pyran-2-yl)oxy)phenol (23.2 g, 119.7 mmol, 52.7% yield). | [storage]
Store at -20°C | [References]
[1] Canadian Journal of Chemistry, 2006, vol. 84, # 9, p. 1174 - 1179
[2] Patent: JP5978938, 2016, B2. Location in patent: Paragraph 0149; 0154
[3] Journal of Materials Chemistry, 2012, vol. 22, # 48, p. 25011 - 25018
[4] Patent: US2009/326186, 2009, A1. Location in patent: Page/Page column 64
[5] Angewandte Chemie - International Edition, 2013, vol. 52, # 16, p. 4356 - 4360 |
|
| Company Name: |
BioPharmaMatrix,Inc. Gold
|
| Telephone: |
0510-86010668 13395169561; |
| Website: |
http://www.biopharmamatrix.com |
| Company Name: |
T&W GROUP
|
| Telephone: |
021-61551611 13296011611 |
| Website: |
www.trustwe.com/ |
|